Last $6.46 USD
Change Today -0.20 / -3.00%
Volume 331.9K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$6.57
Previous Close
$6.66
Day High
$6.66
Day Low
$6.40
52 Week High
09/13/13 - $9.89
52 Week Low
04/30/13 - $5.00
Market Cap
184.6M
Average Volume 10 Days
296.3K
EPS TTM
$-2.03
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer and Vice President
Total Annual Compensation: $190.6K
President of Progenitor Cell Therapy, LLC and...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc., California Stem Cell, Inc. - M&A Call

To discuss the definitive agreement to acquire California Stem Cell, Inc

Neostem, Inc. Appoints Adel Nada as Vice President of Immunotherapy

NeoStem, Inc. appointed Adel Nada as vice president of immunotherapy. In this position, Dr. Nada will be responsible for developing the company's T Regulatory Cell Program Dr. Nada comes to NeoStem from Baxter Healthcare, where from 2012 to 2014 he was Senior Medical Director, Cardiovascular Cellular Therapies.

NeoStem, Inc. Appoints Adel Nada as Vice President, Immunotherapy

NeoStem, Inc. announced the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells to treat diseases caused by imbalances in the immune system. Dr. Nada comes to the company from Baxter Healthcare, where from 2012 to 2014 he was Senior Medical Director, Cardiovascular Cellular Therapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $6.46 USD -0.20

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.73 USD +0.10
BioTime Inc $2.78 USD +0.05
Cytomedix Inc $0.56 USD -0.0295
Cytori Therapeutics Inc $2.34 USD -0.01
Pluristem Therapeutics Inc $3.54 USD +0.06
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.